Ambalal Sarabhai Enterprises Ltd
NSE: AMBASARABH BSE: 500009
₹24.99
(3.35%)
Sun, 15 Mar 2026, 01:57 pm
Market Cap1.85B
PE Ratio17.36
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KAmbalal Sarabhai Enterprises Analysis
dividend
- Unable to evaluate Ambalal Sarabhai Enterprises's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Ambalal Sarabhai Enterprises's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Ambalal Sarabhai Enterprises is profitable, therefore cash runway is not a concern.
- Ambalal Sarabhai Enterprises is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 2.1x debt.
- Ambalal Sarabhai Enterprises's cash and other short term assets cover its long term commitments.
- Ambalal Sarabhai Enterprises had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
- Interest payments on debt are well covered by earnings (EBIT is 4.6x coverage).
- Ambalal Sarabhai Enterprises's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not well covered by operating cash flow (7.1%, less than 20% of total debt).
- Ambalal Sarabhai Enterprises's level of debt (179.9%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Ambalal Sarabhai Enterprises board of directors is about average.
- The average tenure for the Ambalal Sarabhai Enterprises management team is less than 2 years, this suggests a new team.
misc
- Ambalal Sarabhai Enterprises is not covered by any analysts.
- Ambalal Sarabhai Enterprises has significant price volatility in the past 3 months.
past
- Ambalal Sarabhai Enterprises has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
- Ambalal Sarabhai Enterprises's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Ambalal Sarabhai Enterprises's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Ambalal Sarabhai Enterprises used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Ambalal Sarabhai Enterprises has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Ambalal Sarabhai Enterprises's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- 500009 outperformed the Market in India which returned -14.5% over the past year.
- Ambalal Sarabhai Enterprises is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Ambalal Sarabhai Enterprises is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Ambalal Sarabhai Enterprises is overvalued based on earnings compared to the India market.
- 500009 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- BSE:500009 is down -12.2% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:500009 is down -12.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800